The Board of Directors of Medi Lifestyle Limited announced that the company's indirect wholly owned subsidiary, HealthPro Marketing Sdn Bhd has signed a distributor agreement with Malaysian Genomics Resource Centre Berhad for the Singapore and Cambodia markets, for marketing, sales and distribution of its cell and cell-free products including Mesenchymal Stem Cell-derived Exosomes. The Distributor Agreement is valid for an initial 1 year and is renewable on an annual basis. HPM shall be granted exclusivity for the sales and distribution of the Products subject to certain targets being met.

Malaysian Genomics, a company listed on Bursa Malaysia, operates the only Bio-Safety Level 2 laboratories in Southeast Asia that is Current Good Manufacturing Practice -approved for cell engineering BSL-2 and cGMP certifications indicate that a laboratory facility has stringent measures for biocontainment standards and ultra-pure laboratory environments to safely work on human cells. Human umbilical cord-derived mesenchymal stem cells (UC-MSCs) are a class of cells with significant self-renewal and multi-lineage differentiation properties, and they are recognised for their therapeutic potential for anti-inflammation, cell regeneration and therapeutic effects against chronic diseases. UC- MSC-derived Exosomes contain valuable lipids, messenger-RNA, micro-RNA, signalling cytokines, and proteins.

Exosomes are powerful elements that can restore cells throughout the human body. They enhance cell-to-cell communication, which is essential for overall cell health to stimulate healing. Exosome therapy is a highly targeted, flexible treatment for conditions like osteoarthritis, musculoskeletal injuries, chronic wound management, and skin regeneration.

The Distributor Agreement with MGRC is not expected to have an impact on the consolidated net tangible assets and earnings per share of the Group for the current financial year ending 31 December 2023. Save for their shareholdings in the Company, none of the Directors or controlling shareholders of the company has any interest, direct or indirect, in the Distributor Agreements. The Directors are also not aware of any substantial shareholders that have an interest, direct or indirect, in the Distributor Agreements.

Shareholders and other investors are reminded to exercise caution while dealing in the shares of the company. In the event that shareholders and other investors are in doubt when dealing in the shares of the Company, they should consult their bankers, stockbrokers, solicitors or other professional advisers. The company will make the appropriate announcements as and when there are material developments.